Evotec wins $74M DOD contract for orthopoxvirus antibodies

Evotec's Just - Evotec Biologics unit received a $74 million contract from the U.S. Department of Defense for rapid development of monoclonal antibodies against mpox, chickenpox and smallpox, from discovery through Phase 1.

“Evotec has secured yet another contract from the Department of Defense (DOD). This time, the U.S. government is committing $74 million for the development of monoclonal antibodies against mpox, chickenpox and smallpox.”fiercebiotech.com

• 1 source
• fiercebiotech.comEvotec's latest DOD contract provides $74M to tackle mpoxJames WaldronJul 5, 2023

Summarized from public sources; check the original articles before acting on it.